Form 4: Dyne Therapeutics CEO John Cox Granted Stock Options

Dyne Therapeutics CEO John Cox was granted stock options to purchase 679,853 shares of common stock on March 25, 2024.

Summary

• John Cox, CEO of Dyne Therapeutics, was granted stock options on March 25, 2024.
• The options allow him to purchase 679,853 shares of Dyne Therapeutics common stock at an exercise price of $26.06 per share.
• The options vest over four years, with 25% vesting on March 25, 2025, and the remainder vesting in equal monthly installments thereafter, contingent upon continuous service.
• The options expire on March 24, 2034.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the granting of stock options aligns the CEO's interests with shareholders and incentivizes long-term performance. It's a standard practice, so not overly exciting, but generally a good sign.

Positives

• The granting of stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to increase the company's value.
• The vesting schedule encourages long-term commitment from the CEO.

Risks

• The value of the stock options is dependent on the future performance of Dyne Therapeutics' stock price.
• If the stock price does not increase above the exercise price of $26.06, the options will be worthless.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.

Industry Context

Granting stock options to executives is a common practice in the biotechnology industry to incentivize performance and align management's interests with those of shareholders. The size and vesting schedule of the options are typical for executive compensation packages in similar companies.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Sarepta Therapeutics and BioMarin Pharmaceutical also utilize stock options to incentivize their executives.
• The vesting schedule of four years with a one-year cliff is a common structure to ensure long-term commitment.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the CEO to increase the company's value.
• Employees may see it as a positive sign of the company's commitment to its leadership.

Key Dates